Closed CHF 6.9M seed round plus an additional CHF 3M tranche led by Genku Ventures (total CHF 9.9M). Leadership changes: Frederik Decouttere moved to CEO; co-founder Riccardo Dainese moved to CCO.
About Alithea Genomics
Swiss biotech developing multiplexed library preparation technologies for RNA sequencing (e.g., BRB-seq, DRUG-seq and 1536-well MERCURIUS DRUG-seq kits) to lower cost and increase throughput for large-scale transcriptomics in drug discovery and toxicology.
Lausanne, Switzerland
Read Company ProfileFrequently Asked Questions
What type of funding round did Alithea Genomics raise?
Alithea Genomics raised a seed round.
How much did Alithea Genomics raise in its seed?
Alithea Genomics raised $9,900,000 CHF in its seed.
When did Alithea Genomics raise its seed?
Alithea Genomics raised its seed on 2026-03-04.
Who invested in Alithea Genomics's seed?
The investors in Alithea Genomics's seed are: Novalis Biotech, Genku Ventures, Several private investors.
What type of investment was Alithea Genomics's seed?
Alithea Genomics's seed was a equity investment.
How will Alithea Genomics use the funds from its seed?
Alithea Genomics plans to use the funds for: Commercialisation and scaling of 1536-well MERCURIUS DRUG-seq kits, Development of new RNA sequencing technologies, Building proprietary transcriptomic datasets to support AI and machine-learning research, Support commercial expansion and product development for drug discovery and toxicology applications.